Beryl W. Dominy
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Beryl W. Dominy.
Advances in Experimental Medicine and Biology | 1991
Dennis J. Hoover; Balusubramanian Veerapandian; J. B. Cooper; David B. Damon; Beryl W. Dominy; Robert Louis Rosati; Tom L. Blundell
In this study we report the X-ray analysis of a complex between the aspartic protease endothiapepsin (EC 3.4.23.6) and an inhibitor bound as a carbonyl hydrate (gem-diol) to the catalytic aspartates of this enzyme, in a manner closely resembling the putative tetrahedral intermediate in proteolytic cleavage of the peptide bond.1 This study was undertaken in order to obtain a closer model of the interactions stabilizing this intermediate than those used in previous analyses, which were based on X-ray crystallographic data obtained from inhibitors lacking one or both of the hydroxyl residues of this species.2,3
European Journal of Pharmacology | 1980
B. Kenneth Koe; Susan W. Koch; Beryl W. Dominy
Imidoline, 1-[2-(N,N-dimethylamino)ethyl]-3-m-chlorophenyl-2-imidazolidinone, has been found to be as potent as chlorpromazine in increasing striatal DOPA accumulation and prolactin secretion in vivo. In contrast, imidoline exhibited only weak inhibitory activity towards dopamine-sensitive adenylate cyclase and 3H-spiroperidol binding to striatal membranes in vitro. These neuroleptic effects in vivo are probably caused by blockade of dopamine receptors since imidoline did not deplete the striatum of dopamine. Imidoline is of interest because its structure is distinct from those of other neuroleptics. A proposed active conformation involves intramolecular hydrogen bonding between the protonated dimethylamino group and the oxygen of the imidazolidinone ring. The spatial relationship between the amine nitrogen and phenyl ring in this conformation allows proper fit of imidoline with key dimensions described for the dopamine receptor.
Advanced Drug Delivery Reviews | 1997
Christopher A. Lipinski; Franco Lombardo; Beryl W. Dominy; Paul J. Feeney
FEBS Letters | 1984
B. L. Sibanda; Tom L. Blundell; Peter M. Hobart; M. Fogliano; Jasjit S. Bindra; Beryl W. Dominy; John M. Chirgwin
Protein Science | 2008
B. Veerapandian; J. B. Cooper; Andrej Šali; Tom L. Blundell; Robert Louis Rosati; Beryl W. Dominy; David B. Damon; Dennis J. Hoover
Archive | 1974
El-Haj Marwan J. Abu; Beryl W. Dominy
Advanced Drug Delivery Reviews | 1997
Christopher A. Lipinski; Franco Lombardo; Beryl W. Dominy; Paul J. Feeney
Advanced Drug Delivery Reviews | 2001
Christopher A. Lipinski; Franco Lombardo; Beryl W. Dominy; Paul J. Feeney
Journal of Organic Chemistry | 1972
M. J. Abu. El-Haj; Beryl W. Dominy; J. D. Johnston; M. J. Haddadin; C. H. Issidorides
Bioorganic & Medicinal Chemistry Letters | 1998
Lawrence A. Reiter; Kevin Koch; Anthony D. Piscopio; Henry J. Showell; Robbin Alpert; Michael S. Biggers; Robert J. Chambers; Maryrose J. Conklyn; Kelvin Cooper; Santo R. Cortina; Joseph DiBrino; Beryl W. Dominy; Cathy A. Farrell; Gary P. Hingorani; Gary J. Martinelli; Mukesh Ramchandani; Kathyrn F. Wright